Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

(2012) E Dean et al.   BRITISH JOURNAL OF CANCER

The Development of MetAP-2 Inhibitors in Cancer Treatment

(2012) S.-Q. Yin et al.   CURRENT MEDICINAL CHEMISTRY

The Antifolates

(2012) Michele Visentin et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

(2012) Elisabet Wahlberg et al.   NATURE BIOTECHNOLOGY

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Profiling Cellular Protein Complexes by Proximity Ligation with Dual Tag Microarray Readout

(2012) Maria Hammond et al.   PLoS One

Positron emission tomography molecular imaging for drug development

(2011) Paul M. Matthews et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

(2011) X. Liu et al.   CLINICAL CANCER RESEARCH

Mechanisms of drug resistance in kinases

(2011) Rina Barouch-Bentov et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The CDK inhibitors in cancer research and therapy

(2011) Jonas Cicenas et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

PARP inhibitors stumble in breast cancer

(2011) Malini Guha   NATURE BIOTECHNOLOGY

Trends in the exploitation of novel drug targets

(2011) Mathias Rask-Andersen et al.   NATURE REVIEWS DRUG DISCOVERY

Identification of Direct Protein Targets of Small Molecules

(2010) Brett Lomenick et al.   ACS Chemical Biology

Deconstructing the Drug Development Process: The New Face of Innovation

(2010) K I Kaitin   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

GSK/Sirtris compounds dogged by assay artifacts

(2010) Charlie Schmidt   NATURE BIOTECHNOLOGY

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas

(2010) John T. Lee et al.   Pigment Cell & Melanoma Research

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression

(2009) D. S. Auld et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Target identification using drug affinity responsive target stability (DARTS)

(2009) B. Lomenick et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Thermodynamic Analysis of Protein Stability and Ligand Binding Using a Chemical Modification- and Mass Spectrometry-Based Strategy

(2008) Graham M. West et al.   ANALYTICAL CHEMISTRY

Pharmacokinetics in Drug Discovery

(2007) Ana Ruiz-Garcia et al.   JOURNAL OF PHARMACEUTICAL SCIENCES